Risk assessment score for adverse pregnancy outcome in systemic lupus erythematosus patients

Egyptian Rheumatology and Rehabilitation

Table 3 Maternal and fetal outcomes in SLE patients according to disease activity

Variable	All SLE patients (n = 116)		Active SLE (n = 38)		Inactive SLE (n = 78)		Test	P
Variable	no.	%	no.	%	no.	%	Test	P
Adverse pregnancy outcome maternal and or fetal	62	53.4	36	94.7	26	33.3	38.72	0.000c*
Gestational age at delivery, mean ± SD, weeks	38.09 ± 1.3		37.6 ± 1.4		38.36 ± 1.08		t = 3.21	.0017a
Maternal complications	no.	%	no.	%	no.	%	Test	P
Gestational diabetes	2	1.7	1	2.6	1	1.3	f	0.55 d
Pregnancy-induced hypertension	6	5.2	4	10.6	2	2.6	f	0.08d
Thromboembolism	2	1.72	2	5.3	0	0.0	f	0.11d
Preeclampsia	8	6.9	7	21.1	1	1.3	f	.001 d*
Eclampsia	1	0.9	1	2.6	0	0.0	f	0.32d
Disease flare during pregnancy	16	13.8	11	28.94	5	6.41	10.9	0.000c*
Disease flare postpartum	12	10.34	9	23.7	3	3.84	f	0.002d*
Preterm delivery	10	8.62	7	18.42	3	3.84	f	0.013d*
Intensive care admission	1	0.9	0	.0	16	1.3	f	0.99d
Fetal complications	no.	%	no.	%	no.	%	Test	P
Abortion	28	24.13	19	50	9	20.6	18.3	0.000c*
Intrauterine fetal death	6	5.2	4	10.6	2	2.6	f	0.08d
Preterm birth	10	8.62	7	18.42	3	3.84	f	0.013d*
Neonatal lupus	2	1.7	2	5.3	0	0	f	0.11d
Neonatal intensive care admission	1	0.9	1	2.6	0	0	f	0.32d

SLE systemic lupus erythematosus. All values are presented as mean ± SD or median (range) or number (%). a Independent t-test, c chi-square test, d Fisher test. Insignificant, P > 0.05; significant, *P ≤ 0.05